Please note that any information that you supply is protected by our Privacy Policy.
Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.
|
In a time where FDA sponsored initiatives such as Lean 6 Sigma, QbD and PAT are set to dominate the future of Pharmaceutical Manufacture, the industry is becoming ever more aware that controlling particle size for API and excipients via physical milling is not ideal, having a dramatically negative effect on a range of newly understood key physicochemical parameters and ultimately drug product performance.